Abstract
Current interventions for irritable bowel syndrome with constipation tend to target single symptoms of the disorder, with multiple symptom relief only achieved through the use of combinations of therapies. Hence, there remains an unmet need for well-tolerated and effective treatments for irritable bowel syndrome with constipation that target abdominal symptoms, including abdominal pain and bowel symptoms.
Financial & competing interests disclosure
J Tack received financial compensation for advisory boards and speaker bureaus from Abbott, Almirall, Alpha Wasserman, AstraZeneca, Danone, Janssen, Menarini, Novartis, Nycomed, Shire, SK Life Sciences, Theravance, Tranzyme and Zeria. These studies were sponsored by Ironwood Pharmaceuticals and Forest Laboratories. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Medical writing assistance was provided by L Donaldson of Complete Medical Communications Ltd and was funded by Almirall.